Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

16 Nov 2026 Evaluate
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark), today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA®1 (axitinib) tablets. According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million*. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1870.30
Dr. Reddys Labs. 1383.30
Cipla 1389.95
Lupin 1951.80
Zydus Lifesciences 1202.70
View more..